A5032682480- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Bladder and Urothelial Cancer Treatments
- Gene expression and cancer classification
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Ferroptosis and cancer prognosis
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Nutrition, Genetics, and Disease
- Single-cell and spatial transcriptomics
- Estrogen and related hormone effects
- Colorectal Cancer Screening and Detection
- DNA Repair Mechanisms
- Hematopoietic Stem Cell Transplantation
- PARP inhibition in cancer therapy
- Genomic variations and chromosomal abnormalities
- Molecular Biology Techniques and Applications
- Cancer-related molecular mechanisms research
- Genetic Associations and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Immune Cell Function and Interaction
Hospital General Universitario Gregorio Marañón
2015-2021
Centro de Investigación Biomédica en Red de Cáncer
2018
GEICAM – Spanish Breast Cancer Group
2018
Spanish National Cancer Research Centre
2010-2016
Center for Research in Environmental Epidemiology
2010-2015
Universitat Pompeu Fabra
2015
University of Liège
2015
Centro de Investigación del Cáncer
2010-2014
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2010
National School of Public Health
2010
Abstract Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness anthracycline-free platinum combinations TNBC is not well known. Here, we report efficacy NA + docetaxel (CbD) TNBC. Experimental Design: The study population includes 190 patients with stage I–III treated uniformly on two independent prospective cohorts. All were...
Abstract Purpose: Prognostic value of pathologic complete response (pCR) and extent attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) overall (OS) according to degree patients treated carboplatin docetaxel NAC. Patients Methods: One-hundred ninety stage I–III TNBC were (AUC6) (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence invasive tumor axilla) Residual...
Abstract Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed evaluate performance TNBCtype-4 classifier in a cohort patients with TNBC treated carboplatin and docetaxel (TCb). Methods: Patients were accrued nonrandomized trial AUC 6 75 mg/m2 for six cycles. Response was evaluated terms pathologic complete (pCR, ypT0/is ypN0) residual burden by Symmans colleagues. Lehmann's...
Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between digital multiplexed gene expression platform, subtype call after running PAM50 assay series of breast cancer patients classified as triple negative by IHC/FISH. The goal this study analyze concordance both platforms overall, calling intrinsic subtypes particular.
Sonic hedgehog (Shh) pathway genetic variations may affect bladder cancer risk and clinical outcomes. Therefore, we genotyped 177 single-nucleotide polymorphisms (SNP) in 11 Shh genes a study including 803 cases controls. We assessed SNP associations with outcomes 419 of non-muscle-invasive (NMIBC) 318 muscle-invasive metastatic (MiMBC). Only three SNPs (GLI3 rs3823720, rs3735361, rs10951671) reached nominal significance association (P ≤ 0.05), which became nonsignificant after adjusting for...
Pathway analysis of genome-wide association studies (GWAS) offer a unique opportunity to collectively evaluate genetic variants with effects that are too small be detected individually. We applied pathway bladder cancer GWAS containing data from 3,532 cases and 5,120 controls European background (n = 5 studies). Thirteen hundred ninety-nine pathways were drawn five publicly available resources (Biocarta, Kegg, NCI-PID, HumanCyc, Reactome), we constructed 22 additional candidate previously...
Objectives: Different types of ‘-omics' data are becoming available in the post-genome era; still a single -omics assessment provides limited insights to understand biological mechanism complex diseases. Genomics, epigenomics and transcriptomics provide insight into molecular dysregulation neoplastic diseases, among them urothelial bladder cancer (UBC). Here, we propose detailed analytical framework necessary achieve an adequate integration three sets ultimately identify previously hidden...
To build a predictive model for urothelial carcinoma of the bladder (UCB) risk combining both genomic and nongenomic data, 1,127 cases 1,090 controls from Spanish Bladder Cancer/EPICURO study were genotyped using HumanHap 1M SNP array. After quality control filters, genotypes 475,290 variants available. Nongenomic information comprised age, gender, region, smoking status. Three Bayesian threshold models implemented including: (1) only information, (2) (3) sources information. The three...
We adapted Bayesian statistical learning strategies to the prognosis field investigate if genome-wide common SNP improve prediction ability of clinico-pathological prognosticators and applied it non-muscle invasive bladder cancer (NMIBC) patients. Adapted sequential threshold models in combination with LASSO were consider time-to-event censoring nature data. studied 822 NMIBC patients followed-up >10 years. The study outcomes time-to-first-recurrence time-to-progression. predictive including...
Increasing evidence points to the role of tumor immunologic environment on urothelial bladder cancer prognosis. This effect might be partly dependent host genetic context. We evaluated association SNPs in inflammation-related genes with non-muscle-invasive (NMIBC) risk-of-recurrence and risk-of-progression.We considered 822 NMIBC included SBC/EPICURO Study followed-up >10 years. selected 1,679 belonging 251 inflammatory genes. The risk-of-progression was assessed using Cox regression...
Characterization of the driver mutations in an individual metastatic breast cancer (MBC) patient is critical to selecting effective targeted therapies. Currently, it believed that limited efficacy many drugs may be due expansion drug resistant clones with different genotypes were already present primary tumor. Identifying genomic alterations these clones, and introducing combined or sequential regimens, could lead a significant increase currently available therapies.The objective this study...
Over the last decade, regularized regression methods have offered alternatives for performing multi-marker analysis and feature selection in a whole genome context. The process of defining list genes that will characterize an expression profile remains unclear. It currently relies upon advanced statistics can use agnostic point view or include some priori knowledge, but overfitting problem. This paper introduces methodology to deal with variable model estimation problems high-dimensional...
<p>Supplemental material contains names of participating institutions for the Spanish MMJ-CAR-2014-01 cohort, details on local guidelines positive family history, tables depicting relationship between pathological response and ER/PR status univariate analysis predictors RCB 0+1. Supplemental Table 1. Pathological Family history breast ovarian cancer 2. by Supplement 3. Predictors 0+1 analysis</p>
<p>Table S1 Response among mutation carriers (number of patients.)</p>
<p>Supplementary methods, tables and figures</p>
<p>Supplemental material contains names of participating institutions for the Spanish MMJ-CAR-2014-01 cohort, details on local guidelines positive family history, tables depicting relationship between pathological response and ER/PR status univariate analysis predictors RCB 0+1. Supplemental Table 1. Pathological Family history breast ovarian cancer 2. by Supplement 3. Predictors 0+1 analysis</p>
<p>Table S1 Response among mutation carriers (number of patients.)</p>
<p>Recurrence-free survival and overall in the patient population</p>